Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 1;29(2):341-346.
doi: 10.1093/annonc/mdx731.

Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors

C Albany  1 , N Adra  2 , A C Snavely  3 , C Cary  4 , T A Masterson  4 , R S Foster  4 , K Kesler  5 , T M Ulbright  6 , L Cheng  6 , M Chovanec  7 , F Taza  2 , K Ku  8 , M J Brames  2 , N H Hanna  2 , L H Einhorn  2
Affiliations

Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors

C Albany et al. Ann Oncol. .

Abstract

Background: To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University (IU) since the publication of the International Germ Cell Cancer Collaborative Group (IGCCCG), and to compare our overall survival (OS) to that of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program.

Patients and methods: We conducted a retrospective analysis of all patients with metastatic germ-cell tumor (GCT) seen at IU from 1998 to 2014. A total of 1611 consecutive patients were identified, of whom 704 patients received an initial evaluation by our MDC (including medical oncology, pathology, urology and thoracic surgery) and started first-line chemotherapy at IU. These 704 patients were eligible for analysis. All patients in this cohort were treated with cisplatin-etoposide-based combination chemotherapy. We compared the progression-free survival (PFS) and OS of patients treated at IU with that of the published IGCCCG cohort. OS of the IU testis cancer primary cohort (n = 622) was further compared with the SEER data of 1283 patients labeled with 'distant' disease. The Kaplan-Meier method was used to estimate PFS and OS.

Results: With a median follow-up of 4.4 years, patients with good, intermediate, and poor risk disease by IGCCCG criteria treated at IU had 5-year PFS of 90%, 84%, and 54% and 5-year OS of 97%, 92%, and 73%, respectively. The 5-year PFS for all patients in the IU cohort was 79% [95% confidence interval (CI) 76% to 82%]. The 5-year OS for the IU cohort was 90% (95% CI 87% to 92%). IU testis cohort had 5-year OS 94% (95% CI 91% to 96%) versus 75% (95% CI 73% to 78%) for the SEER 'distant' cohort between 2000 and 2014, P-value <0.0001.

Conclusion: The MDC approach to GCT at high-volume cancer center associated with improved OS outcomes in this contemporary dataset. OS is significantly higher in the IU cohort compared with the IGCCCG and SEER 'distant' cohort.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan–Meier estimates of progression-free survival (A) and overall survival (B) according to IGCCCG risk stratification.
Figure 2.
Figure 2.
Kaplan–Meier estimates of overall survival of patients with newly diagnosed metastatic testicular GCT at the IU (1998–2014) and patients in NCI SEER (2000–2014).
See this image and copyright information in PMC

Comment in

References

    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7–30. - PubMed
    1. Williams SD, Birch R, Einhorn LH. et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316(23): 1435–1440. - PubMed
    1. de Wit R, Roberts JT, Wilkinson PM. et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001; 19(6): 1629–1640. - PubMed
    1. Einhorn LH, Williams SD, Loehrer PJ. et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. JCO 1989; 7: 387–391. - PubMed
    1. Culine S, Kerbrat P, Kramar A. et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 2007; 18(5): 917–924. - PubMed

Publication types